BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35440764)

  • 1. Well differentiated papillary mesothelial tumor: a new name and new problems.
    Churg A; Galateau-Salle F
    Mod Pathol; 2022 Oct; 35(10):1327-1333. PubMed ID: 35440764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in mesothelial pathology.
    Churg A
    Histopathology; 2024 Jan; 84(1):136-152. PubMed ID: 37694811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A; Prabhakaran S; Pulford E; Hocking AJ; Godbolt D; Ziad F; Pandita A; Wessels A; Hussey M; Russell PA; Klebe S
    Pathology; 2024 May; ():. PubMed ID: 38789301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesothelioma In Situ Mimicking Well-differentiated Papillary Mesothelial Tumor.
    Galateau-Salle F; Hamilton T; MacNeill A; Hofman V; Sequeiros R; Sagan C; Le Stang N; Churg A
    Am J Surg Pathol; 2023 May; 47(5):611-617. PubMed ID: 36876759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelioma of Uncertain Malignant Potential (MUMP) of the Tunica Vaginalis: Proposal for Reclassification as "Complex Mesothelial Tumor of the Tunica Vaginalis".
    Ding CC; Van Roo J; Kryvenko ON; Ye H; McKenney JK; Epstein JI
    Am J Surg Pathol; 2024 Apr; 48(4):387-394. PubMed ID: 38270560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.
    Vitlarov N; Burtscher E; Pfeiffenberger E; Wahl A; Hodja V; Jasarevic Z; Kashofer K; Offner FA
    Virchows Arch; 2023 Dec; 483(6):873-878. PubMed ID: 37428268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature.
    Symes E; Tjota M; Cody B; Kindler H; Mitchell O; Witmer H; Turaga K; Mueller J; Krausz T; Husain AN; Li H
    Histopathology; 2024 Feb; 84(3):492-506. PubMed ID: 38084880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
    Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
    Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
    Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
    Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
    Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
    Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.
    Lee HE; Molina JR; Sukov WR; Roden AC; Yi ES
    Hum Pathol; 2018 Sep; 79():168-176. PubMed ID: 29763720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.
    Zafar R; Schrader LJ; Cheville JC; Schoolmeester JK; Roden AC; Aubry MC; Yi ES; Raghunathan A; Herrera-Hernandez L; Thompson RH; Boorjian SA; Leibovich BC; Keeney GL; Jimenez RE; Gupta S
    Hum Pathol; 2022 Oct; 128():31-47. PubMed ID: 35809685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
    Hwang HC; Pyott S; Rodriguez S; Cindric A; Carr A; Michelsen C; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A; Sheffield BS; Galateau-Salle F
    Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
    Hung YP; Chirieac LR
    Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.